The Global Market for Drug-Eluting Stents is Projected to Reach US$5.9 Billion by 2022

Increasing Incidence of Cardiovascular Diseases & Novel Stent Developments to Drive the Drug-Eluting Stents Market, According to a New Report by Global Industry Analysts, Inc.

GIA launches comprehensive analysis of industry segments, trends, growth drivers, market share, size and demand forecasts on the global Drug-Eluting Stents market. The global market for Drug-Eluting Stents is projected to reach US$5.9 billion by 2022, driven by factors such as rapidly aging world population, rise in prevalence of cardiovascular diseases and development of novel stents.

Drug-eluting stents (DES) represent an important development in interventional cardiology. These advanced coronary stents are coated with a polymer that releases a pharmacologic agent to block the growth of scar tissue and cell proliferation. Major factors driving the DES market include rising demand for minimally invasive surgery and increasing incidence of cardiovascular diseases led by demographic factors such as expanding geriatric population and increase in lifestyle diseases such as hypertension, obesity, and diabetes. The market is also expected to benefit from the development of novel stents with lower side effects such as bleeding or damage to the blood vessel, allergic reactions to stent material or dye, stent thrombosis, and stent occlusion, among others.

Product differentiation remains the theme of new product development efforts. Over the years the DES market has evolved led by advancements such as thinner stent struts, lower drug dosage and shift towards more biocompatible polymers resulting in improved help deliverability and better healing profiles. Research is currently intensifying in the polymer-free DES space with efforts focused on mechanisms to control the drug release rate and improve anti-restenotic efficacy. Some of the developments include surface modification with micropores on the surface of the stent. The future is expected to witness the introduction of multiple DES platforms including stents with varied strut thickness, varied polymer combinations, and different drugs with manufacturers focused on innovations aimed at addressing unmet clinical needs to treat a wider range of patient anatomies. The market, in the forthcoming years is expected to gain from encouraging clinical trial results of some of the pipeline DES.

As stated by the new market research report on Drug-Eluting Stents, the United States represents the largest market worldwide. Asia-Pacific with a CAGR of 4.9% over the analysis period ranks as the fastest growing market led by factors such as such as growing population, rapid urbanization and the resulting increase in each individual’s exposure to cardiovascular disease (CVD) risk factors as a result of globalization of unhealthy food and lifestyle practices, improving access to healthcare services, focus on quality of healthcare services and rising healthcare spending.   

Major players covered in the report include Abbott Laboratories, AlviMedica, Arterius Limited, Boston Scientific Corporation, Biotronik SE, Cook Medical, KYOTO MEDICAL, Medtronic plc STENTYS SA, and Terumo Corporation, among others.

The research report titled “Drug-Eluting Stents: A Global Strategic Business Report” announced by Global Industry Analysts Inc., provides a comprehensive review of market trends, issues, drivers, mergers, acquisitions and other strategic industry activities of major companies worldwide. The report provides market estimates and projections for all major geographic markets including the US, Canada, Japan, Europe (France, Germany, Italy, UK, Spain, Russia and Rest of Europe), Asia-Pacific (China, India, Rest of Asia-Pacific), Latin America and Rest of World.

Global Industry Analysts, Inc. 6150 Hellyer Ave., San Jose CA 95138, USA, All Rights Reserved.